Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

• Published in: The American journal of cardiology Vol. 117; no. 7; pp. 1151 - 1159
• Main Authors: Bongini, Carolina, MD, Ferrantini, Cecilia, MD, PhD, Girolami, Francesca, BSc, Coppini, Raffaele, MD, PhD, Arretini, Anna, MD, Targetti, Mattia, MD, Bardi, Sara, BSc, Castelli, Gabriele, MD, Torricelli, Francesca, BSc, Cecchi, Franco, MD, Ackerman, Michael J., MD, PhD, Padeletti, Luigi, MD, Poggesi, Corrado, MD, Olivotto, Iacopo, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-04-2016; Elsevier Limited
• Subjects: Adult; Age; Age Factors; Aged; Atrial Fibrillation - epidemiology; Atrial Fibrillation - genetics; Cardiac arrhythmia; Cardiac Myosins - genetics; Cardiomyopathy; Cardiomyopathy, Hypertrophic - complications; Cardiomyopathy, Hypertrophic - genetics; Cardiovascular; Carrier Proteins - genetics; Clinical Decision-Making; Cohort Studies; Electrocardiography; Embolisms; Female; Genetic counseling; Genetic Testing; Genotype; Genotype & phenotype; Humans; Male; Middle Aged; Mutation; Myosin Heavy Chains - genetics; Patients; Predictive Value of Tests; Prevalence; Proteins; Sinuses; Software
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2015.12.058

Genes associated with hypertrophic cardiomyopathy (HC) are not uniformly expressed in the atrial myocardium. Whether this may impact susceptibility to atrial fibrillation (AF) is unresolved. To analyze the prevalence and clinical correlates of AF in relation to genotype in a large HC cohort, prevalence and clinical profile of AF were assessed in 237 patients with HC, followed for 14 ± 10 years. Patients were divided into 3 genetic subgroups: (1) MYBPC3 (58%), (2) MYH7 (28%), and (3) “other genotypes” (14%; comprising TNNT2 , TNNI3 , TPM1 , MYL2 , complex genotypes, Z-line, and E-C coupling genes). Left atrial size was similar in the 3 subsets. AF occurred in 74 patients with HC (31%), with no difference among groups (31% in MYBPC3 , 37% in MYH7 and 18% in other genotypes, p = 0.15), paroxysmal/persistent AF (12%, 18%, and 12%, respectively; p = 0.53), paroxysmal/persistent evolved to permanent (12%, 12%, and 3%, p = 0.36) or permanent AF (7%, 7%, and 3%, p = 0.82). Age at AF onset was younger in the group with other genotypes (37 ± 10 years) compared to the first 2 groups (53 ± 14 and 51 ± 17, respectively; p = 0.05) because of early onset associated with complex genotypes and a specific JPH2 mutation associated with abnormal intracellular calcium handling. At multivariate analysis, independent predictors of AF were atrial diameter (p ≤0.05) and age at diagnosis (p = 0.09), but not genetic subtype (p = 0.35). In conclusion, in patients with HC, genetic testing cannot be used in clinical decision making with regard to management strategies for AF. Genotype is not predictive of onset or severity of AF, which appears rather driven by hemodynamic determinants of atrial dilatation. Exceptions are represented by rare genes suggesting specific molecular pathways for AF in genetic cardiomyopathies.